论文部分内容阅读
目的 :将胃癌McAb配伍提高McAb与人胃癌组织的反应性 ,为肿瘤定位诊断及导向治疗提供有效的McAb配伍。方法 :采用ABC免疫过氧化物酶染色观察了胃癌McAb及配伍McAb与胃癌组织的反应性。结果 :2 6例胃癌组织经ABC免疫过氧化物酶染色显示 ,3G9、BB4 3经配伍后 ,在相同浓度下 ,与单一McAb相比 ,阳性率由单一McAb的 5 0 0 % ,65 4%提高到配伍后的 96 0 % (P <0 0 1 )。McAb 3G9、BB4 3配伍后作用于正常胃癌组织 ,均呈阴性反应。结论 :合理采用配伍的McAb可提高McAb与人胃癌组织的反应性 ,降低抗原表达的异质性 ,从而提高McAb的载体效应。
Objective: To improve the reactivity of McAb with human gastric carcinoma by combining gastric cancer McAb, and to provide effective McAb compatibility for tumor localization diagnosis and targeted therapy. Methods: The reactivity of gastric cancer McAb, compatible McAb and gastric cancer tissues was observed by ABC immunoperoxidase staining. RESULTS: The ABC immunoperoxidase staining of 26 cases of gastric carcinoma showed that after compatibility of 3G9 and BB4 3, at the same concentration, compared with a single McAb, the positive rate was from 50%, 654% of a single McAb. Increased to 960% after compatibility (P < 0 01). McAb 3G9 and BB4 3 acted on normal gastric cancer tissues and all showed negative reactions. Conclusion: The rational use of compatible McAb can improve the reactivity of McAb with human gastric cancer tissues, reduce the heterogeneity of antigen expression, and increase the carrier effect of McAb.